抑制CK2/ING4通路促进非小细胞肺癌免疫疗法
Qian Gou1,2,3, Huiqing Chen2, Mingjun Chen2
1Department of Oncology, the Affiliated Wujin Hospital of Jiangsu University, Changzhou, Jiangsu, 213017, P. R. China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|October 23, 2023
概括
这项研究揭示,CK2激酶通过降低ING4.4来促进非小细胞肺癌的免疫逃生. 抑制CK2恢复ING4,增强T细胞活性,并增强癌症免疫疗法.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 编程死亡配体1 (PD-L1) 表达有助于瘤免疫逃生,阻碍了抗瘤免疫疗法.
- 氨酸激酶2 (CK2) 是一种涉及瘤进展的激酶,但其在免疫逃生中的作用尚不清楚.
研究的目的:
- 为了研究CK2对非小细胞肺癌 (NSCLC) 免疫逃逸的影响.
- 阐明在NSCLC中将CK2,ING4和PD-L1连接在一起的分子机制.
主要方法:
- 对临床NSCLC样本的分析,以关联CK2和ING4表达.
- 在体外实验中研究CK2介导的ING4.4的酸化和泛化.
- 评估对CK2调节的反应中T细胞活性和瘤免疫逃脱.
- 在临床前模型中评估联合CK2抑制剂和PD-1抗体治疗.
主要成果:
- ING4诱导PD-L1降解,增强T细胞活性并抑制NSCLC免疫逃逸.
- 高CK2表达与NSCLC中低ING4水平相关.
- CK2在S150酸化ING4,从而导致其被JFK基因化酶所致的无化和降解.
- CK2基因淘汰稳定了ING4,增加了T细胞活性,并抑制了NSCLC的免疫逃逸.
- 结合CK2抑制和PD-1抗体治疗显示出增强的抗瘤作用.
结论:
- 通过准ING4进行降解,CK2促进NSCLC的免疫逃生.
- 向CK2代表了一种新的策略,用于增强NSCLC的抗瘤免疫疗法.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Tumor Immunotherapy
538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


